Pappas Capital is a global venture capital and commercial development firm founded in 1994 and based in Durham, North Carolina, investing in next-generation life science, agriculture, and technology companies across three lines of business: Pappas Ventures, Specialized Fund Management, and Translational Medicine.
31% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $42.5M (across 64 rounds with reported amounts).
Portfolio
52
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Barry Myers, MD, PhD
Senior Venture Partner
EM
Ernie Mario
Founder and Senior Venture Partner
Franz Humer, PhD
Venture Partner and Senior Advisor
PY
Peter Young
Senior Venture Partner
Russel Kaufman, MD
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
71 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Solu | Series A | $41M | Apr 2025 |
| SSolu Therapeutics | Series A | $41M | Apr 2025 |
 Reneo | Series B | $47.3M | Feb 2025 |
 EarthOptics | Unknown | — | Nov 2024 |
 Enlaza Therapeutics | Series A | $100M | Apr 2024 |
 Horizon Quantum | Series A | $18.1M | Apr 2023 |
 VFlowTech | Series A | $3M | Feb 2023 |
| HHorizon Quantum Computing | Series A | $18.1M | Jan 2023 |
 Us2.ai | Unknown | $15M | Apr 2022 |
 Plexium | Growth | $102M | Feb 2022 |
| AAvenge Bio | Series A | — | Jan 2022 |
| AAvenge Bio | Seed | — | Jan 2022 |
| Us2.ai | Series A | $15M | Jan 2022 |
| AAvengebio | Series A | $45M | Jan 2022 |
| RReneo Pharmaceuticals Inc | Series B | $95M | Dec 2020 |
| Reneo | Series A | $95M | Dec 2020 |
| Reneo | Series B | $95M | Dec 2020 |
 BioAtla | Series D | $72.5M | Jul 2020 |
 Amplyx Pharmaceuticals, Inc. | Series C | — | May 2020 |
 Allievex | Series A | — | Oct 2019 |
| RReneo Pharmaceuticals Inc | Series A | $50M | May 2019 |
 Ribometrix | Series A | $30M | Nov 2018 |
| VVelosBio | Series A | $58M | Oct 2018 |
| VVelosBio | Series B | $137M | Feb 2018 |
| CCurasen | Series A | $54.5M | Jan 2018 |
Page 1 of 3
Top Co-Investors
New Enterprise Associates17 shared
RiverVest Venture Partners10 shared
Domain Associates9 shared
Rock Springs Capital8 shared
Novo Capital7 shared
Sofinnova Partners6 shared
Alexandria Venture Investments6 shared
Adage Capital Management5 shared
Pivotal Life Sciences4 shared
Arix Bioscience4 shared
Takeda Ventures, Inc.4 shared
Eli Lilly and Company4 shared
Morningside4 shared
Alta Partners4 shared
Tekla Capital Management4 shared
Longitude Capital4 shared
Amzak Health4 shared
Abingworth LLP4 shared
DCVC3 shared
RA Capital Management3 shared
Last updated: 7 October 2026